Canadian Cancer Trials Group Bulletins

General


Canadian Cancer Trials Group News From ASCO 2012

A number of abstracts related to Canadian Cancer Trials Group trials or trials which included Canadian Cancer Trials Group participation were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, June 1-5, 2012, including the results of two breast cancer Canadian Cancer Trials Group-led studies that were highlighted in the media and by ASCO.

The first study was an exploratory study within Canadian Cancer Trials Group MA.27 (A Randomized Phase III Trial of Exemestane versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer) that included almost 1,300 postmenopausal women with a diagnosis of early breast cancer who used aromatase inhibitors and who had osteoporosis. The researchers found that the women with osteoporosis experienced improved event-free survival and distant disease-free survival suggesting that the treatments used by thousands of women to prevent or treat osteoporosis may actually have a bigger role than just promoting bone health.

You can read more about this study by visiting the Canadian Cancer Society's website (www.cancer.ca) or by using this link ... http://www.cancer.ca/Canada-wide/About%20us/Media%20centre/CW-Media%20releases/CW-2012/ASCO.aspx?sc_lang=en.

The link to the abstract can be found on the American Society of Clinical Oncology website using this link ... http://abstract.asco.org/AbstView_114_93668.html


The second study was the Canadian Cancer Trials Group-led MA.31 trial -- A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women with HER2/neu Positive Metastatic Breast Cancer

Interim results of the trial presented at ASCO by Dr. Karen Gelmon, Co-Chair of the Canadian Cancer Trials Group Breast Site Committee, show that trastuzumab prolongs progression-free survival compared with lapatinib when added to taxane-based first-line therapy for women with HER2-positive metastatic breast cancer.

The results of this interim analysis were highlighted in the ASCO Daily News which you can read using this link ... http://chicago2012.asco.org/ASCODailyNews/LBA671.aspx.

The link to the abstract can be found on the ASCO website using this link ... http://abstract.asco.org/AbstView_114_102986.html.

For a complete listing of abstracts presented, please use this link ... http://www.ctg.queensu.ca/public/publications/ASCO-2012.pdf